This page contains brief information about pomalidomide and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials.
FDA label information for this drug is available at DailyMed.
Use in Cancer
Pomalidomide is approved to treat:
- AIDS-related Kaposi sarcoma in adults whose disease has gotten worse after treatment with highly active antiretroviral therapy (HAART).¹
- Kaposi sarcoma in adults who are HIV negative.¹
- Multiple myeloma. It is used with dexamethasone to treat adults whose disease has gotten worse during or after treatment with at least two other therapies that included lenalidomide and a proteasome inhibitor.
¹This use is approved under FDA’s Accelerated Approval Program. As a condition of approval, confirmatory trial(s) must show that pomalidomide provides a clinical benefit in these patients.
Pomalidomide is only available as part of a special program called Pomalyst REMS (Risk Evaluation and Mitigation Strategies).
Pomalidomide is also being studied in the treatment of other types of cancer.
More About Pomalidomide
Definition from the NCI Drug Dictionary - Detailed scientific definition and other names for this drug.
MedlinePlus Information on Pomalidomide - A lay language summary of important information about this drug that may include the following:
- warnings about this drug,
- what this drug is used for and how it is used,
- what you should tell your doctor before using this drug,
- what you should know about this drug before using it,
- other drugs that may interact with this drug, and
- possible side effects.
Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for. This patient information sheet applies only to approved uses of the drug. However, much of the information may also apply to unapproved uses that are being studied.
Clinical Trials Accepting Patients
Find Clinical Trials for Pomalidomide - Check for trials from NCI's list of cancer clinical trials now accepting patients.